Investegate |RedHill Biopharma Announcements | RedHill Biopharma: 62% COVID19 Mortality Reduction with Oral Opaganib
Investegate announcements from RedHill Biopharma, 62% COVID19 Mortality Reduction with Oral Opaganib
Source: investegate.co.uk
Page 2 - Markl Levitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Markl Levitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Markl Levitt Today - Breaking & Trending Today
RedHill Biopharma Ltd. reports 62% mortality reduction in moderately severe COVID-19 patients treated with oral opaganib in new analysis of data from global Phase 2/3 study
"These new findings support the potential for opaganib's use in hospitalized, moderately severe COVID-19 patients - a key group of patients that are at...
Source: proactiveinvestors.com
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the...
Source: prnewswire.com
RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients
62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the
Source: adnkronos.com
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study
Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstrated potent inhibition of Beta and Gamma variants and is expected to be effective against emerging variants, including Delta and Delta Plus RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and f...
Source: ryt9.com